Zydus Lifesciences' heart rhythm disorder drug approved by USFDA
Apixaban blocks the activity of certain clotting substances in the blood.

Image: Zydus (Representative)
According to an exchange filing, Indian pharma firm Zydus Lifesciences, has received final approval from the United States Food and Drug Administration (USFDA) for Apixaban Tablets, 2.5 mg and 5 mg . Apixaban blocks the activity of certain clotting substances in the blood.
ALSO READ

It is used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.
It is also used for treatment of blood clots in the veins of legs or lungs, and reduces the risk of them occurring again. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad
RECENT STORIES
-
Revenue Generated From Prada's Kolhapuri Chappal Sales Belongs To Indian Artisans," Says BJP Leader;... -
Bhopal Man Arrested For Duping Over 80 Youths With Fake Amazon Job Offers -
Indore’s Sanitation Model Steals the Spotlight At National Conference In Gurugram -
Madhya Pradesh: Anti-Venom, Anti Rabies Crisis During Monsoon -
Gauri Vrat 2025: Know Why Unmarried Women Observe This Auspicious Fast?